ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
Top Cited Papers
- 20 November 2023
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (33) , 5107-5117
Abstract
Deep and durable responses with zanubrutinib plus obinutuzumab in patients with R/R FL.Keywords
This publication has 35 references indexed in Scilit:
- SAKK 35/14 RANDOMIZED TRIAL OF RITUXIMAB WITH OR WITHOUT IBRUTINIB FOR UNTREATED PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN NEED OF THERAPYHematological Oncology, 2023
- Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 studyThe Lancet Oncology, 2022
- The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpointThe Lancet Oncology, 2022
- Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trialThe Lancet Oncology, 2022
- Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE studyAnnals of Hematology, 2021
- Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trialThe Lancet Oncology, 2021
- Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2021
- Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trialThe Lancet Oncology, 2020
- Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 studyThe Lancet Haematology, 2019
- Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trialThe Lancet Oncology, 2016